We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





IVD Market Exceeded USD 50 Billion in 2011

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A market research company reports that the world market for in vitro diagnostics (IVD) is estimated at USD 50.9 billion for 2011.

According to a report by the healthcare market research publisher, Kalorama Information (New York, NY, USA) growth in the IVD market is driven by an aging population, product innovations, and sales to emerging markets. More...
Kalorama revealed its findings as the industry meets and assesses its progress at the annual 2012 meeting of the American Association for Clinical Chemistry (AACC), which is being held in Los Angeles (CA, USA) from July 15-July 19, 2012.

The revenue estimate for 2011 includes all laboratory and hospital-based products, and over-the-counter (OTC) product sales. The report found that the IVD market has grown but it will be challenged with a sharp decline in pricing for diagnostic tests in Europe and consolidation in the US, which could lead to price erosion.

“A number of world events bode well for the future of medical devices: an aging worldwide population and demand for new hospitals in developing countries,” said Shara Rosen, Kalorama diagnostic analyst and author of the report. “Increasing numbers of people between the ages of 45 and 75 years in the industrialized world consume more healthcare services such as heart and cancer tests.”

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

The new availability of choices, undoubtedly good for medical care, poses problems for the physician who must choose correctly from among the numerous new IVD products, and for payers to pay for new technologies that may still be unproven.

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

“IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care,” remarked Shara Rosen.

Related Links:

Kalorama Information



New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image Credit: Adobe Stock

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.